Clinical trials: Age-Related Atrophy
Age-related Macular Degeneration
Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy
The purpose of this study is to define phenotypic variations in atrophic Age-Related Macular Degeneration (AMD) and to identify predictive factors for disease progression based on fundus autofluorescence imaging.
- Trial name
- NCT00393692
- Where
- 7 sites in Germany
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Age-related Macular Degeneration, Geographic Atrophy
Geographic Atrophy and Intravitreal Ranibizumab Injections
Given the aging population who will be affected by wet AMD and lack of effective GA treatment, it is crucial to assess the safety profile of repeated ranibizumab injections in AMD patients with GA, particularly the possible risk…
- Trial name
- NCT02372916
- Testing
- Ranibizumab
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Sarcopenia, Muscle Loss
Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)
Up to 66 healthy elderly individuals (at least 65 years old) are recruited as subjects. They will be recruited as a subgroup to protocol ID: H-4-2013-070.
- Trial name
- CALM (NCT02115698)
- Testing
- Heavy Resistance Training, Light Intensity Training, Protein Whey
- Where
- Denmark
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Retinal Degeneration, Retinal Diseases
SGLT2 Inhibitors in Geographic Atrophy
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration.
- Conditions
- Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy
- Trial name
- NCT07174687
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Washington University School of Medicine
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Falls (Accidents) in Old Age, Falls
Evaluation of the Relationship Between Fall Risk, Muscle Strength, and Anticholinergic Burden in Geriatric Patients Presenting to the Emergency Department
Falls are common among older adults and can lead to serious injury. This study looks at whether taking many medications (polypharmacy), the anticholinergic burden of those medications (a measure of side effects that can affect…
- Conditions
- Falls (Accidents) in Old Age, Falls, Anticholinergics, Sarcopenia
- Trial name
- NCT07813143
- Where
- Turkey (Türkiye)
- Volunteers
- 333 people
- Sponsor
- Gazi University
Age-Related Macular Degeneration, Geographic Atrophy
Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study
This study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Visual Field Defect, Central Scotoma of Both Eyes
- Trial name
- OMEGA (NCT05963646)
- Testing
- Natural history study
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Institute of Molecular and Clinical Ophthalmology Basel
Dry AMD, Geographic Atrophy
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Trial name
- VIRETTA (NCT07433088)
- Testing
- Object recognition and selection task
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Streetlab
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Dry Age-related Macular Degeneration
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- EXPLORE (NCT04437368)
- Testing
- GT005
- Where
- 55 sites in United States, Australia and 6 more
- Volunteers
- 98 people
- Sponsor
- Gyroscope Therapeutics Limited
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
- Trial name
- OMEGA (NCT00485394)
- Testing
- OT-551
- Where
- 17 sites in United States
- Volunteers
- 198 people
- Sponsor
- Othera Pharmaceuticals
Age-Related Macular Degeneration, Geographic Atrophy
The Natural History of Geographic Atrophy Progression (GAP) Study
The objective of the 18-month trial is to evaluate the natural history of geographic atrophy by assessing the rate of progression of the geographic atrophic lesion over time.
- Trial name
- NCT00599846
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Alcon Research
Geographic Atrophy
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
- Trial name
- AiiM OLE (NCT07807969)
- Testing
- Vonaprument
- Where
- 7 sites in United States
- Volunteers
- 605 people
- Sponsor
- Annexon, Inc.
Geographic Atrophy
Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
This study will seek to enroll 50 persons who have central or non-central geographic atrophy (GA) associated with age-related macular degeneration (AMD). GA in treated eye must be between 0.75 disk areas (DA) and 8 DA.
- Trial name
- Sirolimus (NCT01675947)
- Testing
- Sirolimus, Lidocaine
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration Advanced, Macular Degeneration, Senile
Visual Rehabilitation Through Acoustic Biofeedback With Retimax Vision Trainer in Patients With Advanced Age-related Macular Degeneration
At present there are no real therapies able to improve visual performance in patients with age-related macular degeneration, atrophic type.
- Conditions
- Macular Degeneration Advanced, Macular Degeneration, Senile, Macular Degeneration, Dry, Macular Scar
- Trial name
- NCT04084587
- Testing
- Retimax Vision Trainer
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- University of Modena and Reggio Emilia
Geographic Atrophy
A Study in Adults With Geographic Atrophy
The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
- Trial name
- NCT07606365
- Testing
- STL303
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 300 people
- Sponsor
- Sitala Bio LTD
Geographic Atrophy
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525600
- Testing
- APL-2
- Where
- 141 sites in United States, Argentina and 13 more
- Volunteers
- 621 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Macular Degeneration
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye.
- Trial name
- NCT00658619
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- Allergan
Geographic Atrophy, Age-Related Macular Degeneration
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye.
- Trial name
- NCT06970665
- Testing
- avacincaptad pegol
- Where
- 14 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc